Energenesis' Diabetic Ulcer Treatment Patent Application Gets 'Notice of Allowance' in US

MT Newswires Live

Aug 11

Energenesis Biomedical (TPE:6657) received a notice of allowance from the U.S. Patent and Trademark Office for its patent application titled "Methods for Treating Diabetic Ulcer," according to a Monday filing with the Taiwan Exchange.

A notice of allowance means a specific trademark has reached the 30-day opposition period following publication but does not amount to registration yet, according to the patent office's website.

The patent protection for its diabetic foot ulcer drug candidate, F703DFU, in the U.S. can be extended till March 25, 2042.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2658962689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658962689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658962689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 14:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658962689","market":"hk","top_or_hot":-1,"title":"Energenesis' Diabetic Ulcer Treatment Patent Application Gets 'Notice of Allowance' in US","media":"MT Newswires Live","content":"<html><body><p> Energenesis Biomedical (TPE:6657) received a notice of allowance from the U.S. Patent and Trademark Office for its patent application titled \"Methods for Treating Diabetic Ulcer,\" according to a Monday filing with the Taiwan Exchange.</p><p>A notice of allowance means a specific trademark has reached the 30-day opposition period following publication but does not amount to registration yet, according to the patent office's website.</p><p>The patent protection for its diabetic foot ulcer drug candidate, F703DFU, in the U.S. can be extended till March 25, 2042.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Energenesis' Diabetic Ulcer Treatment Patent Application Gets 'Notice of Allowance' in US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnergenesis' Diabetic Ulcer Treatment Patent Application Gets 'Notice of Allowance' in US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-11 14:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Energenesis Biomedical (TPE:6657) received a notice of allowance from the U.S. Patent and Trademark Office for its patent application titled \"Methods for Treating Diabetic Ulcer,\" according to a Monday filing with the Taiwan Exchange.</p><p>A notice of allowance means a specific trademark has reached the 30-day opposition period following publication but does not amount to registration yet, according to the patent office's website.</p><p>The patent protection for its diabetic foot ulcer drug candidate, F703DFU, in the U.S. can be extended till March 25, 2042.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USRD","symbol_name":"THEMES US R&D CHAMPIONS ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658962689","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658962689","pubTimestamp":1786428208,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Energenesis Biomedical  received a notice of allowance from the U.S. Patent and Trademark Office for its patent application titled \"Methods for Treating Diabetic Ulcer,\" according to a Monday filing with the Taiwan Exchange.A notice of allowance means a specific trademark has reached the 30-day opposition period following publication but does not amount to registration yet, according to the patent office's website.The patent protection for its diabetic foot ulcer drug candidate, F703DFU, in the U.S. can be extended till March 25, 2042.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"USRD":"THEMES US R&D CHAMPIONS ETF"},"translate_title":"Energenesis 糖尿病溃疡治疗专利申请在美国获得“许可通知”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"USRD":0.7},"content_text":"Energenesis Biomedical (TPE:6657) received a notice of allowance from the U.S. Patent and Trademark Office for its patent application titled \"Methods for Treating Diabetic Ulcer,\" according to a Monday filing with the Taiwan Exchange.A notice of allowance means a specific trademark has reached the 30-day opposition period following publication but does not amount to registration yet, according to the patent office's website.The patent protection for its diabetic foot ulcer drug candidate, F703DFU, in the U.S. can be extended till March 25, 2042.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}